---
figid: PMC5507649__onco12152-fig-0002
figtitle: Targeting the ALK signaling pathway
organisms:
- NA
pmcid: PMC5507649
filename: onco12152-fig-0002.jpg
figlink: /pmc/articles/PMC5507649/figure/onco12152-fig-0002/
number: F2
caption: 'Targeting the ALK signaling pathway. (A): Upon ligand binding, dimerization
  of wild‐type ALK leads to kinase activation and phosphorylation. ALK activation
  results in the initiation of a number of signaling cascades involved in promoting
  cell proliferation and survival. (B): Unlike wild‐type ALK, the STRN‐ALK fusion
  protein is constitutively dimerized and activated allowing for hyperactivation of
  downstream signaling pathways and oncogenic growth. Emerging clinical and preclinical
  data indicates that the STRN‐ALK fusion protein may be sensitive to ALK inhibitors,
  such as crizotinib or ceritinib; therefore, ALK inhibitors may be a potential therapeutic
  strategy for patients with these alterations.'
papertitle: Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture‐Based
  Assay of Circulating Tumor DNA.
reftext: Andrea Z. Lai, et al. Oncologist. 2017 Jul;22(7):774-779.
year: '2017'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9063673
figid_alias: PMC5507649__F2
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC5507649__F2
ndex: f3ca33bd-dea0-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5507649__onco12152-fig-0002.html
  '@type': Dataset
  description: 'Targeting the ALK signaling pathway. (A): Upon ligand binding, dimerization
    of wild‐type ALK leads to kinase activation and phosphorylation. ALK activation
    results in the initiation of a number of signaling cascades involved in promoting
    cell proliferation and survival. (B): Unlike wild‐type ALK, the STRN‐ALK fusion
    protein is constitutively dimerized and activated allowing for hyperactivation
    of downstream signaling pathways and oncogenic growth. Emerging clinical and preclinical
    data indicates that the STRN‐ALK fusion protein may be sensitive to ALK inhibitors,
    such as crizotinib or ceritinib; therefore, ALK inhibitors may be a potential
    therapeutic strategy for patients with these alterations.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Alk
  - Su(var)3-9
  - mk
  - ras
  - Ras64B
  - Ras85D
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Raf
  - Akt
  - Dsor1
  - Mtk
  - Erk7
  - rl
  - ALK
  - PTN
  - STRN
  - STAT3
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - Phosphate
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
